Pharmaceutical intermediates

Eltrombopag Olamine Intermediates

7 pharmaceutical intermediates for Eltrombopag Olamine. Indication: Aplastic Anemia; Thrombocytopenia; Idiopathic Thrombocytopenic Purpura (ITP); Chronic Hepatitis C.

提交项目 All intermediates

About Eltrombopag Olamine

Originator: Glaxosmithkline (Gsk)
Indication: Aplastic Anemia; Thrombocytopenia; Idiopathic Thrombocytopenic Purpura (ITP); Chronic Hepatitis C
Approved Date: 09/08/2009
DS/DP: 07/13/2025

Available intermediates

7 intermediates currently listed for Eltrombopag Olamine. Request specifications, documentation or a quotation for any item below.

Eltrombopag Olamine intermediates
Product Name	CAS No.	Molecular Formula	Physical Properties
3'-Amino-2'-Hydroxybiphenyl-3-Carboxylic Acid	376592-93-7	/	/
2'-Hydroxy-3'-Nitro-Biphenyl-3-Carboxylic Acid	376591-95-6	/	/
2'-Methoxy-3'-Nitro-Biphenyl-3-Carboxylic Acid	376591-94-5	/	/
3-Methyl-1-(3,4-dimethylphenyl)-2-pyrazolin-5-one	18048-64-1	/	/
2-(3,4-Dimethylphenyl)-1,2-dihydro-5-methyl-3H-pyrazol-3-one	277299-70-4	/	/
1-Bromo-2-Methoxy-3-Nitrobenzene	98775-19-0	/	/
2-(benzyloxy)-1-bromo-3-nitrobenzene	688363-79-3	/	/

Other programs under E

Edoxaban tosylate monohydrate Elacestrant Elagolix Sodium Eldecalcitol Elinzanetant Elobixibat Eltrombopag Eluxadoline

Building toward Eltrombopag Olamine?

Tell us the step you need covered and the specification you are filing against. We will confirm supply, documentation and lead time.

提交项目联系团队

我们能如何帮助您？

获取最新活动与法规动态洞察

直接发送到您的邮箱

在此获取行业洞察与 Unibest 动态

联系我们 →